Multispecific Binding Proteins Engaging NKG2D, CD16, and Tumor Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including those for blood and bone marrow cancers, are not effective for all patients and can have substantial adverse side effects, while existing cancer immunotherapies, such as bi-specific T-cell engagers, do not fully leverage the potential of natural killer (NK) cells for targeted cancer cell destruction.
Innovation Solution
Development of multi-specific binding proteins that engage both the NKG2D and CD16 receptors on NK cells, along with tumor-associated antigens like KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL, to activate NK cells and enhance their cancer-killing capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then cancer cells can be targeted, but treatment effectiveness varies and adverse side effects are substantial
Solution Approach 1:
The treatment is segmented into multiple specific binding proteins, each designed to target distinct components of the NK cell activation pathway (NKG2D receptor, CD16 receptor, and tumor-associated antigens). This segmentation allows for specialized targeting that improves effectiveness while reducing off-target effects compared to conventional single-mechanism treatments.
Solution Approach 2:
The multi-specific binding proteins perform multiple functions simultaneously: they engage NK cells through NKG2D and CD16 receptors while also binding to tumor-associated antigens. This multi-functionality enables a single therapeutic agent to activate NK cells and target cancer cells, improving treatment reliability and reducing the need for multiple separate treatments that would accumulate side effects.
2Adaptability or versatility
If bi-specific T-cell engagers are used, then T-cell activation is achieved, but NK cell potential is not fully leveraged
Solution Approach 1:
The binding proteins are designed with multiple specificity: they can engage both T-cell and NK cell pathways through NKG2D and CD16 receptors, while simultaneously targeting tumor-associated antigens. This multi-functionality extends immunotherapy coverage to include NK cells, which are critical for cancer destruction, thereby improving reliability without sacrificing versatility.
Solution Approach 2:
The invention merges the functions of T-cell engagers and NK cell activators into a single multi-specific binding protein. By combining NKG2D binding, CD16 binding, and tumor antigen targeting capabilities in one molecule, the therapy achieves both T-cell and NK cell activation, leveraging the full potential of natural killer cells for cancer destruction while maintaining broad immunotherapy coverage.
3Reliability
If multi-specific binding proteins are developed, then NK cell activation is enhanced, but protein structure and function become more complex
Solution Approach 1:
The complex multi-specific binding protein is segmented into distinct functional modules: an NKG2D binding domain, a CD16 binding domain, and a tumor antigen binding domain. Each domain can be independently designed, optimized, and manufactured, which simplifies the overall development process while maintaining the complex multi-specific functionality required for reliable NK cell activation.
Data Source
AI summary
Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.